Mitch C. Hill - Sep 12, 2024 Form 4 Insider Report for Inari Medical, Inc. (NARI)

Role
Chief Financial Officer
Signature
/s/ Shannon Trevino, attorney-in-fact for Mitch C. Hill
Stock symbol
NARI
Transactions as of
Sep 12, 2024
Transactions value $
-$134,014
Form type
4
Date filed
9/13/2024, 04:35 PM
Previous filing
Sep 5, 2024
Next filing
Oct 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NARI Common Stock Options Exercise $1.37K +3K +1.67% $0.46 183K Sep 12, 2024 Direct F1
transaction NARI Common Stock Sale -$71.4K -1.61K -0.88% $44.38 181K Sep 12, 2024 Direct F1, F2
transaction NARI Common Stock Sale -$40.8K -891 -0.49% $45.80 180K Sep 12, 2024 Direct F1, F3
transaction NARI Common Stock Sale -$23.2K -500 -0.28% $46.34 180K Sep 12, 2024 Direct F1, F4
holding NARI Common Stock 1.6K Sep 12, 2024 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NARI Stock Options (Right to Buy) Options Exercise $0 -3K -4.88% $0.00 58.5K Sep 12, 2024 Common Stock 3K $0.46 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $44.13 to $44.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $45.24 to $46.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $46.24 to $46.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 Options vested with respect to 25% of the shares on April 30, 2020 and vested with respect to the remaining shares in 36 equal monthly installments thereafter.